The Latest Breaking News from AstraZeneca

AstraZeneca strikes $40 million AI drug discovery deal with insitro

AstraZeneca has entered a collaboration with insitro to explore new treatment options for challenging liver and heart diseases. The partnership involves a $40 million upfront payment and potential milestones totaling approximately $1.46 billion. Insitro will utilize its AI platform to identify biological drivers for metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Following…

The Economic Times · 18h ago

HRSA Names 10 Drugmakers and 21 Drugs for 340B Rebate Pilot as Hospitals Weigh Options Before January Launch

HRSA approved 10 drugmakers and 21 drugs, including Eliquis and Jardiance, for its 340B rebate pilot starting Jan. 1 as hospitals weigh legal options.

Medical Daily · Oct 5

EGFR Lung Cancer Patients Await a November 14 FDA Decision on Ivonescimab Plus Chemotherapy After Tagrisso Stops Working

The FDA is due to decide by Nov. 14 on ivonescimab plus chemotherapy for EGFR lung cancer after Tagrisso. What patients and families can ask now.

Medical Daily · Oct 1

Tumor Genetic Tests Point Rare Cancer Patients Toward Off-Label Drugs That Insurers Often Refuse to Cover

Tumor genetics can point to a drug approved for another cancer, but insurers often refuse to pay. What rare cancer patients can do.

Medical Daily · Sep 25

European drugmakers say they are ‘losing ground’ to US and Chinese rivals

Some of continent’s biggest pharma firms write to national leaders calling for action to safeguard the sector

The Guardian - UK · Sep 22

Global Market: European shares rise as oil slide boosts risk appetite

European shares rose as technology stocks led gains and falling oil prices eased inflation concerns. The STOXX 600 advanced 0.56%, while investors also tracked the upcoming Trump-Xi meeting.

The Economic Times · Sep 21

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is…

The Economic Times · Sep 21

First-Line Enhertu Delayed HER2-Mutant Lung Cancer Progression by Six Months Over Keytruda Plus Chemotherapy, but Survival Remains Unsettled

Enhertu delayed HER2-mutant lung cancer progression by a median of six months versus Keytruda plus chemo in a Phase 3 trial. Survival is unresolved.

Medical Daily · Sep 17

NHS Approves Breast Cancer Drug Rejected Two Years Ago After Trump Deal Raises NICE Spending Limit

NICE has approved Enhertu for eligible women in England after a new drug deal and higher cost-effectiveness threshold made the treatment affordable for NHS funding.

International Business Times UK · Sep 17

New cancer treatment gives lifeline to stranded women

Women who suffer from breast cancer, endometriosis or other conditions that require ovarian suppression now have a new drug included on the PBS.

AAP · Sep 17